Opening an Investigational New Drug (IND) application dossier can allow a sponsor to take advantage of the FDA’s drug development expertise and ensure the development program will meet the agency’s expectations at the time of the marketing application.
In a webinar replay, Veristat experts explore the minimum required content for an IND submission and the strategic considerations for developing more than the minimum necessary data before filing an IND.